Methods of preparing pharmaceutical solid state forms
The invention provides and describes solid state 17α-ethynyl-5α-androstane-3α,17β-diol including amorphous and crystalline forms and specific polymorphic forms thereof. Anhydrates and solvates of 17α-ethynyl-5α-androstane-3α,17β-diol include Form III anhydrate and Form I solvate. The invention further relates to solid and suspension formulations containing 17α-ethynyl-5α-androstane-3α,17β-diol in a described solid state form and use of the formulations to treat cancers or precancers such as prostate cancer or breast cancer in subjects or human patients. The invention also relates to methods to make liquid formulations from solid state forms of 17α-ethynyl-5α-androstane-3α,17β-diol and uses of such formulations in treating the described conditions.
1. A method to make crystalline anhydrate Form III 17α-ethynyl-5α-androstane-3α,17β-diol that is characterized by or has (i) an X-ray powder diffraction pattern with peak positions of 9.85, 11.33, 15.96, 16.48 and 18.95±0.10 degrees 2-theta or peak positions of 15.96, 16.48 and 18.95±0.10 degrees 2-theta and one two or three peak positions at 9.30, 11.33, 13.45, 16.16 or 17.42±0.10 degrees 2-theta, (ii) an IR-Raman spectroscopy spectrum with peak positions at 1236, 1190 and 490 cm −1 , optionally with one, two or three peak positions at 1458, 1435, 619, 604, 526, 237 or 206 cm −1 or is represented by FIG. 5A or FIG. 5B , and/or (iii) a differential scanning calorimetry thermogram with a prominent endotherm at 164° C. obtained using a temperature ramp of 10° C./min and has a thermogravimetric analysis weight loss of 0.5% or less when heated between 40° C. to 105° C. using a temperature ramp of 10° C./min, said method comprising,
sufficiently drying at ambient temperature (about 22-27° C.) under vacuum crystalline solvate Form I 17α-ethynyl-5α-androstane-3α,17β-diol,
or sufficiently heating crystalline solvate Form I 17α-ethynyl-5α-androstane-3α,17β-diol at a temperature(s) from above ambient temperature to a maximum of about 75° C.,
until the dried or heated material shows a loss on heating of less than 0.5% by weight when heated to 50° C.±5°.
2. The method of claim 1 wherein the crystalline solvate Form I 17α-ethynyl-5α-androstane-3α,17β-diol starting material is essentially free of the other crystalline or amorphous forms of 17α-ethynyl-5α-androstane-3α,17β-diol.
3. The method of claim 2 wherein the crystalline solvate Form I 17α-ethynyl-5α-androstane-3α,17β-diol starting material is at least 95% pure.